9 completed, 2 terminated, 1 unknown, 1 withdrawn. 13 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 9, Terminated 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 2, Unknown 1, Withdrawn 1 |
Follow Stage IV Skin Melanoma: new trials by email Literature Review of Stage IV Skin Melanoma trials Research Report on Stage IV Skin Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab - Lymphoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Completed | Rutgers, The State University of New Jersey | 14 | 2017-10-03 | 2023-12-06 |
| Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification Imatinib Mesylate, Laboratory Biomarker Analysis, Pembrolizumab - Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma | Phase 1 / Phase 2 | Withdrawn | Joanne Jeter | 2016-11-04 | 2018-04-05 | |
| Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 | Completed | Emory University | 25 | 2016-10-04 | 2026-03-09 |
| SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine Laboratory Biomarker Analysis, Nivolumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Spine | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 17 | 2016-06-23 | 2021-11-30 |
| A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases nivolumab, ipilimumab - Stage IIIC Skin Melanoma, Stage IV Skin Melanoma | Phase 1 / Phase 2 | Completed | Universitair Ziekenhuis Brussel | 56 | 2016-03-01 | 2019-01-24 |
| TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim - Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Terminated | Mayo Clinic | 4 | 2016-02-05 | 2018-09-05 |
| Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer Radiation Therapy (RT), MK-3475 - Head and Neck Squamous Cell Carcinoma, Metastatic Renal Cell Cancer | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 41 | 2015-02-05 | 2025-05-15 |
| Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine, Laboratory Biomarker Analysis - Recurrent Melanoma, Stage IIIB Skin Melanoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 10 | 2013-03-26 | 2022-07-22 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 1 | Completed | Roswell Park Cancer Institute | 18 | 2012-03-01 | 2016-10-04 |
| Study With T-cel Receptor Gene Therapy in Metastatic Melanoma TCR transduced T-cells, Biopsy, Blood taking - Stage IV Skin Melanoma, Eye; Melanoma | Phase 1 / Phase 2 | Unknown | The Netherlands Cancer Institute | 12 | 2012-03-01 | 2018-11-02 |
| Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma Cisplatin, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis - Recurrent Melanoma, Stage IV Skin Melanoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 14 | 2010-08-01 | 2019-11-18 |
| Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Gamma-Secretase Inhibitor RO4929097, Cediranib Maleate, Pharmacological Study - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2010-05-01 | 2014-12-23 |
| Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery gp100:209-217(210M) Peptide Vaccine, HPV 16 E7:12-20 Peptide Vaccine, Laboratory Biomarker Analysis - Recurrent Melanoma, Stage IA Skin Melanoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2002-10-01 | 2015-01-26 |
Melanoma (13) · Carcinoma, Renal Cell (5) · Brain Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (4) · Breast Neoplasms (3) · Astrocytoma (2) · Colorectal Neoplasms (2) · Glioblastoma (2) · Lung Neoplasms (2) · Oligodendroglioma (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Urinary Bladder Neoplasms (2) · Uveal Melanoma (2)
Neoplasms (13) · Neoplasms by Histologic Type (13) · Neoplasms by Site (13) · Neoplasms, Germ Cell and Embryonal (13) · Neoplasms, Nerve Tissue (13) · Neuroectodermal Tumors (13) · Neuroendocrine Tumors (13) · Nevi and Melanomas (13) · Skin Diseases (13) · Skin Neoplasms (13) · Skin and Connective Tissue Diseases (13) · Lung Diseases (6) · Respiratory Tract Diseases (6) · Respiratory Tract Neoplasms (6) · Thoracic Neoplasms (6)
pembrolizumab (4) · Nivolumab (3) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (2) · Radiosurgery (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Biopsy (1) · Cisplatin (1) · Cyclophosphamide (1) · Imatinib Mesylate (1) · Ipilimumab (1) · Peptides (1) · Platinum (1) · Protein Subunit Vaccines (1) · Radiation (1) · Radiotherapy (1)
National Cancer Institute (NCI) (3) · Roswell Park Cancer Institute (2) · Emory University (1) · Joanne Jeter (1) · Mayo Clinic (1) · Rutgers, The State University of New Jersey (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · The Netherlands Cancer Institute (1) · Universitair Ziekenhuis Brussel (1)
United States (9) · Belgium (1) · Canada (1) · Netherlands (1)
Bart Neyns, MD Phd (1) · Biren Saraiya (1) · Jennifer Johnson, MD, PhD (1) · Joanne Jeter, MD (1) · John Kane (1) · Kunle Odunsi (1) · Lawrence Kleinberg (1) · Mark Dickson (1) · Mohammad K. Khan, MD, PhD (1) · Peter Cohen (1) · Sebastien Hotte (1) · Walter Urba (1)
PMID 27663515, PMID 35780243, PMID 39462179, PMID 40132910
N01CM62206 (1), P30CA008748 (1), P30CA015083 (1), P30CA016056 (1), P30CA016058 (1), P30CA072720 (1), P30CA138292 (1), R01CA158318 (1), R21CA099265 (1), U01CA069856 (1), U01CA132123 (1)